Monoclonal Antibodies

The HyACT technology is relevant to a broad range of drugs, including monoclonal antibodies.

In preclinical models, Alchemia's HyACT technology has been shown to improve the anticancer activity of newer therapies including monoclonal antibodies such as Avastin (bevacizumab, Genentech Inc. / F.Hoffmann-La Roche Ltd.) and Erbitux (cetuximab, ImClone Systems Inc. / Bristol Myers-Squibb / Merck kGaA).